Ralstonia mannitolilytica-Induced Septicemia and Homology Analysis in Infected Patients: 3 Case Reports

Cai-Xia Liu, Chun Yan, Pan Zhang, Fang-Qu Li, Jing-Hong Yang, and Xiang-Yang Li

1Department of Clinical Laboratory, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
2Department of Clinical Laboratory, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine, Wenzhou Children's Hospital, Wenzhou, Zhejiang Province, China
3Department of Clinical Laboratory, Gongli Hospital, Second Military Medical University, Shanghai, China

*Corresponding author: Xiang-Yang Li, Department of Clinical Laboratory, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. Tel: +86-57788816381, E-mail: xiangyli99@163.com

Received 2015 November 04; Revised 2016 April 21; Accepted 2016 June 07.

Abstract

Background: Ralstonia mannitolilytica is an emerging opportunistic pathogen. Hospital outbreaks of Ralstonia spp. are mainly associated with contaminated treatment water or auxiliary instruments.

Objectives: In this report, we summarize the clinical infection characteristics of R. mannitolilytica, the drug-susceptibility testing of the bacterial strains, and the results of related infection investigations.

Patients and Methods: We retrospectively analyzed the clinical information of 3 patients with R. mannitolilytica.

Results: The patients’ primary-onset symptoms were chills and fever. The disease progressed rapidly and septic shock symptoms developed. Laboratory tests indicated progressively decreased white blood cells and platelets, as well as significant increases in certain inflammation indicators. The effect of treatment with Tazocin was good. The growth period of R. mannitolilytica in sterile distilled water was > 6 months. The pulsed-field gel electrophoresis (PFGE) results revealed that the infectious strains from these 3 patients were not the same clonal strain. This bacterium was not detected in the nosocomial infection samples.

Conclusions: Our results suggest that R. mannitolilytica-induced septicemia had an acute disease onset and rapid progression. The preferred empirical antibiotic was Tazocin. In these 3 cases, the R. mannitolilytica-induced septicemia was not due to clonal transmission.

Keywords: Drug Susceptibility, Pulsed-Field Gel Electrophoresis, Septicemia, Nosocomial Infection, Ralstonia mannitolilytica

1. Background

Ralstonia mannitolilytica is an emerging opportunistic pathogen that is widely present in external environments, such as water, soils, and plant surfaces (1). Ralstonia mannitolilytica rarely causes clinical infections, but once it does, it can lead to more serious infections, such as sepsis, meningitis, and osteomyelitis. There have been pediatric outbreaks of R. mannitolilytica in the United States due oxygen transport equipment contamination (1). Hospital outbreaks of Ralstonia spp. are mainly associated with the contamination of treatment water or auxiliary treatment instruments (1-5). There have been several reported cases of systemic infections caused by R. mannitolilytica (6, 7), mostly occurring in immunocompromised patients. Clinical isolation of R. mannitolilytica is rare in China, while separation from the blood is even rarer (8).

Ralstonia mannitolilytica-caused septicemia is a relatively rare clinical diagnosis, and its drug resistance is serious. Three cases of bloodstream infections with R. mannitolilytica occurred at our hospital between October and November 2013, all of which developed after gastric cancer surgery or a hepatic hemangioma. There is no typical clinical manifestation of R. mannitolilytica infection, and the lack of sufficient experience with its diagnosis and treatment limits doctors’ understanding of this disease.

2. Objectives

In this report, we summarize the clinical infection characteristics of 3 cases, and analyze their risk factors. We also report the drug susceptibility testing and nosocomial infection investigation process, hoping to contribute to the understanding of this infectious bacteria.

3. Patients and Methods

3.1. Patients

The retrospective review of these cases and the collection of their follow-up data were approved by the hospital ethics committee. All patients signed written informed consent forms.
The 3 cases of *R. mannitolilytica*-induced septicemia in our hospital all occurred after tumor surgery. All of these patients developed postoperative fever with a maximum temperature of 39.8 °C during October and November 2013 at the 2nd Affiliated Hospital of Wenzhou Medical University. The patients were 1 man and 2 women, with an average age of 61.7 ± 8.7 years. During disease onset, all 3 of the patients had septic shock symptoms, including chills, fever, reduced or undetectable blood pressure, increased heart rate, and decreased urine output. When the disease became severe, the patients were immediately transferred to the intensive care unit (ICU). The laboratory tests indicated a progressive reduction in the numbers of white blood cells (WBCs) and platelets, and significant increases in C-reactive protein (CRP), procalcitonin (PCT), and endotoxins. *R. mannitolilytica* was detected in the blood cultures. The patients’ information, including underlying diseases, infection symptoms, antimicrobial drug use, catheterization, mechanical ventilation, laboratory detection indicators, and clinical outcomes, are shown in Table 1.

3.2. Isolation, Culture, and Identification of Bacterial Strains

Blood was drawn from the patients under aseptic conditions, then 5 mL samples of the blood were injected into aerobic and anaerobic culture flasks and cultured with the blood culture instrument (Bact/ALERT® 3D 120, bioMerieux Inc., Marcy L’Etoile, France). The culture results were positive 24 hours later, and were transferred into sheep blood agar plates, chocolate plates, and MacConkey agar plates (all purchased from Yilan Bio Co., Ltd. Hangzhou, China). Anaerobic gas bag cultivation was adopted and blood was cultured at 35°C; aerobic cultures were maintained in an incubator at 35°C containing 5% CO₂. Bacterial identification was performed using the automated microbial identification system VITEK Compact-2 (bioMerieux Inc., Marcy L’Etoile, France).

3.3. Drug-Susceptibility Testing

The drug-susceptibility tests were performed using the mass spectrometry microbial identification system VITEK MS (bioMerieux Inc., Marcy L’Etoile, France) and the agar dilution method. The results were analyzed according to the instructions of the Clinical and laboratory standards institute (CLSI) (9).

3.4. Growth Experiments in Sterile Distilled Water

In order to simulate the actual living environment of environmental pathogenic bacteria, the growth experiment was performed in sterile distilled water. The isolated strains were prepared as bacterial suspensions at a turbidity of 0.5 McFarland standards (approximately 10⁷ colony-forming units [CFU]/mL). A volume of 50 µL of suspension was sterilely removed to a clean bottle containing 5 mL of sterile distilled water, to make a 10⁻¹ CFU/mL bacterial solution. Samples were then cultured at 37°C, room temperature, or 4°C. Each week, the samples were inoculated on blood agar plates to observe the bacterial growth.

3.5. Homology Analysis of Bacterial Strains

Four strains (blood samples in Cases 1, 2, and 3; catheter sample in Case 2) of clinically isolated *R. mannitolilytica* were used for the pulsed-field gel electrophoresis (PFGE) homology analysis of chromosomal DNA. The bacterial strains were digested overnight with protease K (Roche Applied Science, Mannheim, Germany) at 50°C, followed by digestion with the restriction endonuclease Spe I (Takara, Dalian, China) at 37°C for 14 hours. The primers were designed according to the literature (10-12), and the sequence of PCR primers were: 5'-3' forward: GGGAAAGCTTGCTTTCCTGTC; 5'-3' reverse: TCCGGGTATAAACAGGGGAC. The reaction system was: 95°C for 5 minutes, 94°C for 40 seconds, 55°C for 40 seconds, 72°C for 1 minute (30 cycles), and 72 °C for 5 minutes.

The DNA samples were subjected to electrophoresis using the CHEF Mapper XA PFGE system (Bio-Rad, CA, USA) at 14°C and 6 V/cm, with a pulse angle of 120° and pulse time of 5 - 35 seconds for 19 hours. After staining with ethidium bromide, the results were observed using a gel image analysis system and analyzed according to the standard determination of PFGE bands developed by Tenover et al. (13). Salmonella H9812 was used as the molecular-weight control.

3.6. Environmental and Item Samples

After the third patient developed the disease, according to the epidemiological characteristics of nosocomial infections, samples were taken from ventilator tubes, ventilator water, tap water, water used for drug injections, disinfectant solutions, medical-record folders, and the fingers of medical care personnel in the Department of Minimally Invasive Surgery. A total of 34 samples were collected, then inoculated in blood agar plates for culturing.

4. Results

4.1. Strain Identification and Drug Susceptibility Testing

Bloodstream infections were confirmed in all 3 patients according to the operating instructions of the VITEK-2 bacterial identification system. The bacterial strain was identified as *R. mannitolilytica* using the VITEK Compact 2, and the biological code was 4203601303500141. The identification rate was > 95%. The identification results from the
Table 1. Summary of Clinical Information of 3 Patients With R. mannitolilytica-Induced Septicemia

|                     | Patient 1                                   | Patient 2                                   | Patient 3                                   |
|---------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| Gender              | Female                                      | Male                                        | Female                                      |
| Age, y              | 74                                          | 56                                          | 55                                          |
| Diagnosis at admission | Gastric T-cell lymphoma                     | Gastric cardia carcinoma                    | Hepatic hemangioma                          |
| Underlying disease(s) | Diabetes mellitus, hypertension, and tuberculous pleurisy for 2 years | -                                           | Diabetes mellitus and hypertension          |
| Surgery             | Distal gastrectomy                          | Radical resection of gastric cardia carcinoma | Partial resection of left hepatic lobe       |
| Central venous catheterization, d | 10                                          | 11                                          | 6                                           |
| Mechanical ventilation, d | 9                                           | 5                                           | 5                                           |
| Clinical manifestation | Chills, persistent fever, increased heart rate, hypotension shock, indifference, decreased urine output |                                |                                              |
| Temperature at disease onset, °C | 39.1                                        | 38                                          | 37.9                                        |
| WBC count, × 10^9/L | (1.6 - 4.39)                                | (18.2 - 2.58)                               | (0.6 - 1.6)                                |
| Platelet count, × 10^9/L | (254 - 59)                                 | (130 - 51)                                 | (73 - 22)                                  |
| CRP, mg/L           | 175.0                                       | 64.00                                       | 138.00                                      |
| Endotoxin, pg/ml    | 33.47                                       | 28.35                                       | 76.16                                       |
| PCT, ng/ml          | > 100.0                                     | 36.680                                      | 52.740                                      |
| Brain natriuretic peptide (BNP), pg/ml | 2.130                                      | -                                          | 1.230                                       |
| Therapeutic drug    | IPM, (TZP2)                                 | IPM, TZP                                    | TZP                                         |
| Outcome             | Cured                                       | Cured                                       | Cured                                       |

Abbreviations: IPM, imipenem; TZP, piperacillin/tazobactam.

VITEK MS also indicated *R. mannitolilytica*; the coincidence rate was 99.9% (Figure 1).

The drug susceptibility test results of 4 strains of *R. mannitolilytica* are shown in Table 2. The strain isolated from Case 1 was sensitive to the majority of the tested antimicrobial agents, which is consistent with the characteristics of the wild-type strain. This patient lived in the mountains and had hematemesis before visiting our hospital for medical treatment. The drug-resistant spectra of Cases 2 and 3 were similar; these strains were resistant to multiple drugs and sensitive only to cotrimoxazole, ceftriaxone, and Tazocin, which is consistent with the characteristics of the drug-resistant strain in nosocomial infections.

4.1. Growth Testing

Through growth testing, we found that the nutritional requirements of *R. mannitolilytica* were very low, as it could survive for a long time in nutrient-deficient distilled water. However, the 4 strains of *R. mannitolilytica* only survived for 5 weeks at 4°C, while they could survive for more than 26 weeks at 37°C or room temperature.

4.2. Homology Analysis

The DNA fingerprint analysis of the 4 strains of *R. mannitolilytica* was performed using the PFGE typing technology. A comparison of the DNA fingerprint profiles of the 4 bacterial strains demonstrated that these 3 patients were infected with different clonal strains of the same bacteria. The PFGE typing result is shown in Figure 2. PFGE results revealed that *R. mannitolilytica* strains from the blood and catheters of Case 2 came from the same clone (Lanes 3 and 4); all separated strains can be confirmed at the band around 398 Kb.

4.3. Environmental Cultures and Control Measures for Infection

*Ralstonia mannitolilytica* was not cultured from all of the collected environmental samples. However, no similar case has occurred again after the implementation of active control measures for nosocomial infections, including changing the batch water used for injection and disinfection solutions, complete disinfection of ventilator tubes, shortening the changing time of the humidifier, complete disinfection of possibly contaminated areas using chlorine-containing disinfectants and ultravi...
Table 2. Results of in Vitro Drug-Susceptibility Testing of R. mannitolilytica

| Antimicrobial drug       | Case 1 Blood | Case 2 Blood | Case 2 Catheter | Case 3 Blood |
|--------------------------|--------------|--------------|-----------------|--------------|
| Cotrimoxazole            | S (≤ 20)     | S (≤ 20)     | S (≤ 20)        | S (≤ 20)     |
| Ampicillin/sulbactam     | S (≤ 2)      | I (16)       | I (16)          | R (≥ 64)     |
| Piperacillin/tazobactam  | S (≤ 4)      | S (≤ 4)      | S (≤ 4)         | S (≤ 4)      |
| Ceftriaxone              | S (4)        | S (2)        | S (2)           | S (4)        |
| Amikacin                 | S (4)        | R (≥ 64)     | R (≥ 64)        | R (≥ 128)    |
| Gentamycin               | S (2)        | R (≥ 16)     | R (≥ 16)        | R (≥ 256)    |
| Tobramycin               | S (2)        | R (≥ 16)     | R (≥ 16)        | R (≥ 64)     |
| Amoxicillin              | R (≥ 32)     | R (≥ 32)     | R (≥ 32)        | R (≥ 64)     |
| Cefazolin                | R (32)       | R (≥ 64)     | R (≥ 64)        | R (≥ 64)     |
| Cefazidime               | S (2)        | R (≥ 64)     | R (≥ 64)        | R (≥ 64)     |
| Cefepime                 | R (≥ 1)      | R (32)       | R (32)          | R (8)        |
| Aztreonam                | S (8)        | R (≥ 64)     | R (≥ 64)        | R (≥ 256)    |
| Imipenem                 | R (≥ 1)      | R (≥ 16)     | R (≥ 16)        | R (≥ 16)     |
| Ciprofloxacin            | S (0.5)      | R (≥ 4)      | R (≥ 4)         | R (≥ 32)     |
| Levofloxacin             | S (0.5)      | R (≥ 8)      | R (≥ 8)         | R (≥ 64)     |
| Nitrofurantoin           | R (≥ 256)    | R (≥ 512)    | R (≥ 512)       | R (≥ 512)    |

Abbreviations: I, intermediate; R, resistant; S, sensitive.

5. Discussion

*Ralstonia* spp. is a non-pathogenic environmental microbe; clinical infection with this species is very rare (6, 14). However, the development of modern medical care, the non-standard use of broad-spectrum antibiotics, and the extensive use of various immunosuppressants has caused increased rates of such infections, mostly *R. pickettii*. There are fewer clinical infections caused by *R. mannitolilytica*; however, it often results in more severe conditions, such as septicemia, recurrent meningitis, myelitis, and peritonitis (6). An *R. mannitolilytica* outbreak occurred in 22 states in the USA in 2005, in which 8 cases were lung infections and 30 had colonizations. The investigation results suggested that this outbreak was caused by contaminated oxygen-delivery devices (3). In 2013, Israel also reported *R. mannitolilytica* infections in infants due to the use of the Vapotherm 2000i oxygen delivery device (5). Grobner et al. (15) reported 5 cases of catheter-related *R. mannitolilytica*-induced bacteremia in leukemia patients in 2007. The contamination source was not finally identified, but it was suggested that intravenous solutions were contaminated and that the use of immunosuppressants and permanent indwelling intravenous devices were the risk factors for this bacterium.

In the present study, the 3 patients were older in age, their immune systems were weaker, and the duration of invasive mechanical ventilation and deep vein catheterization was longer; therefore, these patients had the risk factors for infection with this bacterium. Their initial clinical symptoms were chills and fever, followed by shock symptoms, such as shortness of breath, increased heart rate, rapidly decreased blood pressure, and indifference; these symptoms were basically consistent with descriptions in the literature (4, 15). Laboratory tests indicated a progressive reduction in the numbers of WBCs and platelets, an increase in the non-specific indicator CRP, and significant increases in specific indicators of bacterial infection, such as endotoxins and PCT; Cases 1 and 3 had increased levels of brain natriuretic peptide (BNP) in the presence of heart failure symptoms.

The PFGE results revealed that both strains in Case 2 were from the same clone; therefore, it could be determined that Case 2 had a catheter-related bloodstream infection. One report has demonstrated that *R. mannitolilytica* can form a biofilm on plastic catheters (7). The 3 patients in this study all had postoperative catheteriza-
Panels A, B, and C are bacteria isolated from Cases 1, 2, and 3, respectively.

colonized in the respiratory or digestive system, thereby causing an endogenous infection during the surgical process.

In addition, the growth testing indicated that these bacteria thrived in a warm and humid environment. These bacteria also have the ability to pass through a 0.2-m filter (16, 17) and are disinfectant-resistant (18). These characteristics are consistent with domestic and international reports. The use of ventilators, oxygen delivery devices, venous catheterization, and contaminated medical water are the high-risk factors for infection with *R. mannitolytica* (1, 5, 15, 18). The PFGE detection assay showed that the DNA fingerprint profiles of the 3 bacterial strains were not the same, indicating that they were isolated nosocomial infection events. This bacterium was not isolated in the environmental specimens, and active nosocomial infection-control measures effectively prevented any reinfections with it. Former reports indicated that *R. mannito-
lytica is prevalent in many different types of water supplies (6, 19). Inconsistent with these reports, we were inclined to define ectopic infections those caused by opportunistic pathogens, but further research is needed to prove this theory.

Currently, there are no clear treatment or CLSI breakpoints for identifying R. mannitolilytica infections. In the course of treatment, we advocate using drug-susceptibility testing to adjust the use of antimicrobial agents. In addition, ceftriaxone, ciprofloxacin, and piperacillin/tazobactam are recommended for empirical treatment. Microbiological-detection personnel should pay attention to the slow growth of this bacterium. It is suggested that the growth condition should be determined after 48 hours of culturing; otherwise, a missed diagnosis is likely to occur. The problems caused by this bacterium occur rapidly and disease progression is fast; therefore, R. mannitolilytica infections should draw sufficient attention from clinical physicians and bacteriology workers in order to respond to the resulting severe consequences.

Acknowledgments

We are grateful to Professor Qiyu Bao of Wenzhou Medical University for providing PFGE equipment.

Footnotes

Author Contribution: Xiang-Yang Li and Cai-Xia Liu defined the research theme. Chun Yan and Pan Zhang interpreted the results. Fang-Qu Li and Jing-Hong Yang co-worked on associated data collection and their interpretation.

Funding/Support: The study was supported by key discipline construction project of Pudong health bureau of Shanghai (PWZx2014-03).

References

1. Jung MA, Sunenshine RH, Noble-Wang J, Coffin SE, St John K, Lewis FM, et al. A national outbreak ofRalstonia mannitolilytica associated with use of a contaminated oxygen-delivery device among pediatric patients. Pediatrics. 2007;119(6):e1061-8. doi: 10.1542/peds.2006-3739. [PubMed: 17645371].

2. Dowsett E. Hospital infections caused by contaminated fluids. Lancet. 1972;2(7764):3338. [PubMed: 4183427].

3. Phillips I, Eylyn S, Laker M. Outbreak of hospital infection caused by contaminated autoclaved fluids. Lancet. 1972;2(7763):1258-60. [PubMed: 4183557].

4. Daxboeck F, Stadler M, Assadian O, Marko E, Hirschl AM, Koller W. Characterization of clinically isolated Ralstonia mannitolilytica strains using random amplification of polymorphic DNA (RAPD) typing and antimicrobial sensitivity, and comparison of the classification efficacy of phenotypic and genotypic assays. J Med Microbiol. 2005;54(Pt 1):55-61. doi: 10.1099/jmm.0.45656-0. [PubMed: 15592356].

5. Block C, Ergaz-Shaltiel Z, Valinsky L, Temper V, Hidalgo-Grass C, Minster N, et al. Deja vu: Ralstonia mannitolilytica infection associated with a humidifying respiratory therapy device, Israel, June to July 2011. Euro Surveill. 2013;18(18):20471. [PubMed: 23725776].

6. Ryan MP, Adley CC. Ralstonia spp.: emerging global opportunistic pathogens. Eur J Clin Microbiol Infect Dis. 2014;33(3):299-304. doi: 10.1007/s10096-013-1975-9. [PubMed: 24057141].

7. Dotti J, Printha N, Orfanou A, Papathanasiou E, Papachristou F. Peritonitis due to Ralstonia mannitolilytica in a pediatric peritoneal dialysis patient. New Microbiol. 2012;35(4):503-6. [PubMed: 2309020].

8. Dong YTZH, Zhu HY. Laboratory test for the detection of sepsis induced by R. mannitolilytica. Zhongguo J Prevent Med. 2014;26:215-6.

9. Dallas SD, McGee L, Limbago B, Patel J, McElmeel ML, Fulcher LG, et al. Development of doxycycline MIC and disk diffusion interpretive breakpoints and revision of tetracycline breakpoints for Streptococcus pneumoniae. J Clin Microbiol. 2013;51(6):1798-802. doi: 10.1128/JCM.00125-13. [PubMed: 23604516].

10. Coenye T, Vandamme P, LiPuma JJ. Infection by Ralstonia species in cystic fibrosis patients: identification of R. pickettii and R. mannitolilytica by polymerase chain reaction. Emerg Infect Dis. 2002;8(7):902-6. doi: 10.3201/eid0807.000472. [PubMed: 12095436].

11. Coenye T, Goris J, De Vos P, Vandamme P, LiPuma J. Classification of Ralstonia pickettii-like isolates from the environment and clinical samples as Ralstonia insidiosa sp. nov. Int J Syst Evol Microbiol. 2001;51(3):pt 4:1075-80. doi: 10.1099/ijs.0.02555-0. [PubMed: 12892129].

12. Song E, Wang M, Shen D. Identification and characterization of a novel Ralstonia sp. PD4, capable of degrading 4-fluorooaniline. Biodegradation. 2014;25(1):83-94. doi: 10.1007/s10532-013-9642-5. [PubMed: 23604516].

13. Tenover FC, Arbeid RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995;33(9):2233-9. [PubMed: 7494007].

14. Marce-Coailes E, Bertolini E, Morente C, Lopez MM. Integrated approach for detection of nonculturable cells of Ralstonia solanacearum in asymptomatic Pelargonium spp. cultivars. Phytopathology. 2006;96(6):694-5. doi: 10.1094/PHYTO-96-8-0949. [PubMed: 18942314].

15. Grobner S, Heeg P, Autenrieth IB, Schulte B. Monoclonal outbreak of catheter-related bacteriaemia by Ralstonia mannitolilytica on two haematology-oncology wards. J Infect. 2007;55(5):539-44. doi: 10.1016/j.jinf.2007.07.021. [PubMed: 17880508].

16. Sundaram S, Auriemma M, Howard GJ, Brandwein H, Leo F. Application of membrane filtration for removal of diminutive bioburden organisms in pharmaceutical products and processes. PDA J Pharm Sci Technol. 1999;53(4):186-201. [PubMed: 10754792].

17. Sundaram S, Lewis M, Eisenhuth J, Howard GJ, Larson B. Method for qualifying microbial removal performance of 0.1 micron rated filters. PDA J Pharm Sci Technol. 2002;56(3):186-201. [PubMed: 12095436].

18. Kahan A, Philippion A, Paul G, Weber S, Richard C, Hazebroucq G, et al. Nosocomial infections by chlorhexidine solution contaminated with Pseudomonas pickettii (Biovar VA-I). J Infect. 2003;46(3):256–63. doi: 10.1016/S0148-9203(03)00050-7. [PubMed: 12611482].

19. Stepauanksas R, Glenn TC, Jago CH, Tuckfield RC, Lindell AH, King CJ, et al. Coselection for microbial resistance to metals and antibiotics in freshwater microcosms. Environ Microbiol. 2006;8(9):1510-4. doi: 10.1111/j.1462-2920.2006.0099L.x. [PubMed: 16913911].